5EAR

Crystal structure of human WDR5 in complex with compound 9d

5EAR の概要

• エントリーDOI: 10.2210/pdb5ear/pdb
• 関連するPDBエントリー: 5EAL 5EAM 5EAP
• 分子名称: WD repeat-containing protein 5, N-[5-(2,3-dihydro-1-benzofuran-7-yl)-2-(4-methylpiperazin-1-yl)phenyl]-3-methylbenzamide, 1,2-ETHANEDIOL, ... (6 entities in total)
• 機能のキーワード: wdr5, compound 9d, structural genomics, structural genomics consortium, sgc, transcription - transcription inhibitor complex, transcription / transcription inhibitor
• 由来する生物種: Homo sapiens (Human)
• 細胞内の位置: Nucleus : P61964
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 70710.21

構造登録者

DONG, A.,DOMBROVSKI, L.,SMIL, D.,GETLIK, M.,BOLSHAN, Y.,WALKER, J.R.,SENISTERRA, G.,PODA, G.,AL-AWAR, R.,SCHAPIRA, M.,VEDADI, M.,Bountra, C.,Edwards, A.M.,Arrowsmith, C.H.,BROWN, P.J.,WU, H.,Structural Genomics Consortium (SGC) (登録日: 2015-10-16, 公開日: 2015-11-04, 最終更新日: 2023-09-27)

主引用文献

Getlik, M.,Smil, D.,Zepeda-Velazquez, C.,Bolshan, Y.,Poda, G.,Wu, H.,Dong, A.,Kuznetsova, E.,Marcellus, R.,Senisterra, G.,Dombrovski, L.,Hajian, T.,Kiyota, T.,Schapira, M.,Arrowsmith, C.H.,Brown, P.J.,Vedadi, M.,Al-Awar, R.
Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).
J. Med. Chem., 59:2478-2496, 2016

PubMed Abstract: WD repeat-containing protein 5 (WDR5) is an important component of the multiprotein complex essential for activating mixed-lineage leukemia 1 (MLL1). Rearrangement of the MLL1 gene is associated with onset and progression of acute myeloid and lymphoblastic leukemias, and targeting the WDR5-MLL1 interaction may result in new cancer therapeutics. Our previous work showed that binding of small molecule ligands to WDR5 can modulate its interaction with MLL1, suppressing MLL1 methyltransferase activity. Initial structure-activity relationship studies identified N-(2-(4-methylpiperazin-1-yl)-5-substituted-phenyl) benzamides as potent and selective antagonists of this protein-protein interaction. Guided by crystal structure data and supported by in silico library design, we optimized the scaffold by varying the C-1 benzamide and C-5 substituents. This allowed us to develop the first highly potent (Kdisp < 100 nM) small molecule antagonists of the WDR5-MLL1 interaction and demonstrate that N-(4-(4-methylpiperazin-1-yl)-3'-(morpholinomethyl)-[1,1'-biphenyl]-3-yl)-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridine-3-carboxamide 16d (OICR-9429) is a potent and selective chemical probe suitable to help dissect the biological role of WDR5.

PubMed: 26958703
DOI: 10.1021/acs.jmedchem.5b01630

実験手法

X-RAY DIFFRACTION (1.8 Å)